Isomorphic Labs
AI-driven drug discovery spinoff from DeepMind using AlphaFold to discover novel medicines.
About
Isomorphic Labs, founded by Demis Hassabis (DeepMind CEO/Alphabet), applies AlphaFold technology to drug discovery. Partnerships with Eli Lilly and Novartis. Raised $600M Series A in 2025. Hassabis and John Jumper won 2024 Nobel Prize in Chemistry.
Technology stack
detected 2026-06-05Est. monthly stack spend~$140/mo
CDN
Cloudflare
Email
Google Workspace
Stack
Webflow
Cookie consent
Cookiebot
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Isomorphic Labs do?
Isomorphic Labs, founded by Demis Hassabis (DeepMind CEO/Alphabet), applies AlphaFold technology to drug discovery. Partnerships with Eli Lilly and Novartis. Raised $600M Series A in 2025. Hassabis and John Jumper won 2024 Nobel Prize in Chemistry.
How much funding has Isomorphic Labs raised?
Isomorphic Labs has raised a total of $4.7B in funding. The most recent round on record is Funding Round.
Where is Isomorphic Labs headquartered?
Isomorphic Labs is headquartered in London, United Kingdom.
When was Isomorphic Labs founded?
Isomorphic Labs was founded in 2021.
What industry does Isomorphic Labs operate in?
Isomorphic Labs operates in Drug Discovery, Biotechnology, AI-Driven Drug Discovery, Foundation Model, Generative AI, Protein Folding.